APOL1 基因型、血压与非糖尿病肾病的非裔美国人的生存。
APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy.
机构信息
Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
出版信息
Kidney Int. 2017 Feb;91(2):276-278. doi: 10.1016/j.kint.2016.10.027.
Several landmark trials have assessed the effects of aggressive hypertension control on the progression of nondiabetic chronic kidney disease. Results generally have been disappointing. With the realization that lowering blood pressure, including with renin-angiotensin system blockade, failed to reliably prevent end-stage kidney disease, studies now are analyzing longer-term effects of hypertension control on survival in chronic kidney disease. This commentary reviews the current findings and extends the discussion to apolipoprotein L1 gene by blood pressure (or gene by environment) interactions.
几项具有里程碑意义的试验评估了积极控制高血压对非糖尿病慢性肾病进展的影响。结果通常令人失望。随着人们认识到降低血压，包括使用肾素-血管紧张素系统阻断剂，都不能可靠地预防终末期肾病，目前的研究正在分析长期控制高血压对慢性肾病患者生存的影响。本文评论了目前的研究结果，并将讨论扩展到了载脂蛋白 L1 基因与血压（或基因与环境）的相互作用。
Zotero 插件